Anticipated at a compound annual growth rate of approximately 4% from 2020 onwards, the market for cancer-supportive care products shows promising expansion. Erythropoietin-stimulating agents are positioned to capture the largest share of revenue, owing to their proven effectiveness in addressing anemia induced by chemotherapy. Notably, the distribution of cancer-supportive care products through hospital pharmacies is …